Ignite Creation Date:
2025-12-25 @ 12:28 AM
Ignite Modification Date:
2026-03-08 @ 4:09 AM
Study NCT ID:
NCT00805467
Status:
TERMINATED
Last Update Posted:
2014-06-25
First Post:
2008-12-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| D4300C00021 | None | None | View |